SIRPA and neoplasm: When combined with CD47 inhibitors (e.g., anti-CD47 monoclonal antibodies), the CD47-SIRPα signaling axis on tumor cells is blocked, lifting the inhibitory signals on TANs and significantly enhancing their phagocytic efficiency (107).